首页 > 最新文献

Central European Journal of Immunology最新文献

英文 中文
Trigeminal neuralgia occurring after the third dose of Pfizer BioNTech COVID-19 vaccine. Complication or coincidence? An illustrative case report and literature review. 三叉神经痛发生在第三剂辉瑞BioNTech COVID-19疫苗后。复杂还是巧合?一篇说明性病例报告及文献回顾。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.125309
Kacper Chrostowski, Michał Piasecki, Joanna Bielewicz

The coronavirus disease 2019 pandemic is an ongoing concern for medical care worldwide. Since its emergence, multiple COVID-19 vaccines have been designed, allowing for more effective control of the pandemic. COVID-19 vaccines, like any other form of medical intervention, may cause adverse and unforeseen side effects, varying in frequency and severity. Determining a correlation between the occurring symptoms and the vaccination is often a challenging task, requiring multiple data sources and reported cases. So far, there have been multiple reports of trigeminal neuralgia developing after COVID-19 vaccination. A 36-year-old woman was admitted to the Emergency Ward due to chronic pain attacks in the left side of her face. The pain appeared two months ago, on the day following the vaccination using the third dose of the Pfizer BioNTech COVID-19 vaccine. At the Neurology Department she was diagnosed with trigeminal neuralgia. Based on the lack of any obvious causes, relation to the vaccination, and other similar reports, we assumed that the trigeminal neuralgia was a complication of the vaccination. Hospital treatment consisted of oxcarbazepine, dexamethasone and pregabalin. Treatment was successful, with transient episodes of exacerbation. Six months after the onset of the disorder the patient remains without pain. We believe that the presented case supports the possibility of trigeminal neuralgia occurring in relation to the Pfizer BioNTech COVID-19 vaccine administration. Additional reports may further contribute to establishing a certain link.

2019年冠状病毒病大流行是全球医疗保健持续关注的问题。自出现以来,已设计出多种COVID-19疫苗,从而能够更有效地控制大流行。与任何其他形式的医疗干预一样,COVID-19疫苗可能会导致不良和不可预见的副作用,其频率和严重程度各不相同。确定出现的症状与疫苗接种之间的相关性往往是一项具有挑战性的任务,需要多个数据来源和报告的病例。到目前为止,已有多例报告显示,接种COVID-19疫苗后出现三叉神经痛。一名36岁妇女因左脸慢性疼痛发作被送入急诊室。这种疼痛出现在两个月前,即注射第三剂辉瑞BioNTech新冠疫苗的第二天。在神经科,她被诊断为三叉神经痛。基于缺乏任何明显的原因,与疫苗接种有关,以及其他类似的报告,我们假设三叉神经痛是疫苗接种的并发症。住院治疗包括奥卡西平、地塞米松和普瑞巴林。治疗是成功的,有短暂的发作。发病6个月后,病人仍无疼痛。我们认为,本病例支持与辉瑞BioNTech COVID-19疫苗接种有关的三叉神经痛发生的可能性。其他报告可能进一步有助于建立某种联系。
{"title":"Trigeminal neuralgia occurring after the third dose of Pfizer BioNTech COVID-19 vaccine. Complication or coincidence? An illustrative case report and literature review.","authors":"Kacper Chrostowski,&nbsp;Michał Piasecki,&nbsp;Joanna Bielewicz","doi":"10.5114/ceji.2023.125309","DOIUrl":"https://doi.org/10.5114/ceji.2023.125309","url":null,"abstract":"<p><p>The coronavirus disease 2019 pandemic is an ongoing concern for medical care worldwide. Since its emergence, multiple COVID-19 vaccines have been designed, allowing for more effective control of the pandemic. COVID-19 vaccines, like any other form of medical intervention, may cause adverse and unforeseen side effects, varying in frequency and severity. Determining a correlation between the occurring symptoms and the vaccination is often a challenging task, requiring multiple data sources and reported cases. So far, there have been multiple reports of trigeminal neuralgia developing after COVID-19 vaccination. A 36-year-old woman was admitted to the Emergency Ward due to chronic pain attacks in the left side of her face. The pain appeared two months ago, on the day following the vaccination using the third dose of the Pfizer BioNTech COVID-19 vaccine. At the Neurology Department she was diagnosed with trigeminal neuralgia. Based on the lack of any obvious causes, relation to the vaccination, and other similar reports, we assumed that the trigeminal neuralgia was a complication of the vaccination. Hospital treatment consisted of oxcarbazepine, dexamethasone and pregabalin. Treatment was successful, with transient episodes of exacerbation. Six months after the onset of the disorder the patient remains without pain. We believe that the presented case supports the possibility of trigeminal neuralgia occurring in relation to the Pfizer BioNTech COVID-19 vaccine administration. Additional reports may further contribute to establishing a certain link.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 1","pages":"75-80"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/14/CEJI-48-50183.PMC10189574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The role of monocytes in malaria infection. 单核细胞在疟疾感染中的作用。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.126650
Keh Min Xuan, Nurhidanatasha Abu Bakar, Khairul Mohd Fadzli Mustaffa, Maryam Azlan

Malaria remains one of the most common human infections worldwide. In endemic areas, malaria is a leading cause of morbidity and mortality and it imposes significant socioeconomic burdens on the people affected. Monocytes are part of the immune system controlling parasite burden and protecting the host against malaria infection. Monocytes play their protective roles against malaria via phagocytosis, cytokine production and antigen presentation. Though monocytes are crucial for clearance of malaria infection, they have also been shown to cause adverse clinical outcomes. In this review, we discuss recent findings regarding the role of monocytes in malaria via mechanisms such as parasite detection and clearance, pro-inflammatory activities, and activation of other immune components. We also highlight the role of different monocyte subsets, and other myeloid cells that are involved in malaria infection. However, more investigations are required in order to explore the exact roles of these monocytes in malaria infection.

疟疾仍然是世界上最常见的人类传染病之一。在流行地区,疟疾是发病和死亡的主要原因,并给受影响的人造成重大的社会经济负担。单核细胞是控制寄生虫负担和保护宿主免受疟疾感染的免疫系统的一部分。单核细胞通过吞噬作用、细胞因子产生和抗原呈递发挥抗疟疾的保护作用。虽然单核细胞对清除疟疾感染至关重要,但它们也被证明会导致不良的临床结果。在这篇综述中,我们讨论了关于单核细胞在疟疾中的作用的最新发现,如寄生虫检测和清除、促炎活性和其他免疫成分的激活。我们还强调了不同的单核细胞亚群和其他参与疟疾感染的骨髓细胞的作用。然而,为了探索这些单核细胞在疟疾感染中的确切作用,还需要更多的研究。
{"title":"The role of monocytes in malaria infection.","authors":"Keh Min Xuan,&nbsp;Nurhidanatasha Abu Bakar,&nbsp;Khairul Mohd Fadzli Mustaffa,&nbsp;Maryam Azlan","doi":"10.5114/ceji.2023.126650","DOIUrl":"https://doi.org/10.5114/ceji.2023.126650","url":null,"abstract":"<p><p>Malaria remains one of the most common human infections worldwide. In endemic areas, malaria is a leading cause of morbidity and mortality and it imposes significant socioeconomic burdens on the people affected. Monocytes are part of the immune system controlling parasite burden and protecting the host against malaria infection. Monocytes play their protective roles against malaria via phagocytosis, cytokine production and antigen presentation. Though monocytes are crucial for clearance of malaria infection, they have also been shown to cause adverse clinical outcomes. In this review, we discuss recent findings regarding the role of monocytes in malaria via mechanisms such as parasite detection and clearance, pro-inflammatory activities, and activation of other immune components. We also highlight the role of different monocyte subsets, and other myeloid cells that are involved in malaria infection. However, more investigations are required in order to explore the exact roles of these monocytes in malaria infection.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 1","pages":"54-62"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/fc/CEJI-48-50545.PMC10189572.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular regulatory mechanism of LILRB4 in the immune response. LILRB4在免疫应答中的分子调控机制。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.125238
Haiyin Liu, Jun Yang, Jing Zhang, Peiyue Zhang, Mengting Zhang, Chaojun Yang, Li Liu, Cuiyuan Huang, Wei Wang, Yuhong Zhai, Jian Yang

Immune diseases are caused by the imbalance of immune regulation. This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a member of leukocyte immunoglobulin-like receptors (LILRs). LILRs are expressed constitutively on the surface of multiple immune cells which associate with membrane adaptors to signal through multi- ple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or immunoreceptor tyro-sine-based activation motifs (ITAMs). Through ITIM, LILRB4 could recruit the src homology domain type-2-containing tyrosine phosphatase 1 or 2 (SHP-1 or SHP-2) into the cell membrane. In addition, many factors can induce the expression of LILRB4, such as vitamin D, interferon and so on. Studies have demonstrated that LILRB4 had a negative regulatory role in various of immune diseases. The present review intends to expound the structure and function of LILRB4, as well as its regulators and receptors in the immune cells, so as to provide a theoretical basis for immune disease therapy.

免疫性疾病是由免疫调节失衡引起的。这种不平衡受到许多因素的调节,既有消极的因素,也有积极的因素。白细胞免疫球蛋白样受体B4 (LILRB4)是白细胞免疫球蛋白样受体(LILRs)的一个成员。lilr在多种免疫细胞表面组成性地表达,这些细胞通过多种细胞质免疫受体酪氨酸抑制基序(ITIMs)或免疫受体酪氨酸激活基序(ITAMs)与膜受体结合,发出信号。LILRB4通过ITIM将src同源结构域2型酪氨酸磷酸酶1或2 (SHP-1或SHP-2)募集到细胞膜内。此外,许多因素可以诱导LILRB4的表达,如维生素D、干扰素等。研究表明,LILRB4在多种免疫疾病中具有负调控作用。本文拟阐述LILRB4的结构和功能,以及其在免疫细胞中的调节因子和受体,为免疫疾病的治疗提供理论依据。
{"title":"Molecular regulatory mechanism of LILRB4 in the immune response.","authors":"Haiyin Liu,&nbsp;Jun Yang,&nbsp;Jing Zhang,&nbsp;Peiyue Zhang,&nbsp;Mengting Zhang,&nbsp;Chaojun Yang,&nbsp;Li Liu,&nbsp;Cuiyuan Huang,&nbsp;Wei Wang,&nbsp;Yuhong Zhai,&nbsp;Jian Yang","doi":"10.5114/ceji.2023.125238","DOIUrl":"https://doi.org/10.5114/ceji.2023.125238","url":null,"abstract":"<p><p>Immune diseases are caused by the imbalance of immune regulation. This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a member of leukocyte immunoglobulin-like receptors (LILRs). LILRs are expressed constitutively on the surface of multiple immune cells which associate with membrane adaptors to signal through multi- ple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or immunoreceptor tyro-sine-based activation motifs (ITAMs). Through ITIM, LILRB4 could recruit the src homology domain type-2-containing tyrosine phosphatase 1 or 2 (SHP-1 or SHP-2) into the cell membrane. In addition, many factors can induce the expression of LILRB4, such as vitamin D, interferon and so on. Studies have demonstrated that LILRB4 had a negative regulatory role in various of immune diseases. The present review intends to expound the structure and function of LILRB4, as well as its regulators and receptors in the immune cells, so as to provide a theoretical basis for immune disease therapy.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 1","pages":"43-47"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/5e/CEJI-48-50171.PMC10189573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare cause of steroid-resistant nephrotic syndrome - a case report. 类固醇抵抗性肾病综合征的罕见病因- 1例报告。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.127534
Paulina Kuran, Emilia Platos, Małgorzata Mizerska-Wasiak, Małgorzata Pańczyk-Tomaszewska

Steroid resistance is a common condition occurring in children with nephrotic syndrome. Until now, over 50 genes involved in steroid-resistant nephrotic syndrome (SRNS) pathogenesis have been identified, among which the most prevalent are NPHS1, NPHS2, CD2AP, and PTPRO. The patterns of inheritance of SRNS are autosomal recessive, autosomal dominant, or mitochondrial, and tissues of those patients show focal segmental glomerulosclerosis (FSGS) signs in histopathological image analysis. We present a case of a 6-year-old girl who was admitted to the pediatric nephrology department due to nephrotic range proteinuria and edema of the lower leg. We started therapy with prednisone at a dose of 45 mg (60 mg/m2), enalapril as a nephroprotection, and antihistamines as an additional treatment. During in-patient treatment, we detected increased blood pressure. Due to persistent proteinuria in spite of 6-week treatment with steroids at the maximal dose, we confirmed disease resistance to steroids. Additionally, FSGS signs were confirmed in kidney biopsy samples. After genetic screening for SRNS and detection of the rare gene mutation NUP93 we reduced prednisone but maintained nephroprotective treatment and administered cyclosporin A. The girl remains currently under the care of nephrologists with normal arterial blood pressure, trace proteinuria in follow-up examination, and normal kidney function. NUP93 mutation is extremely rare; therefore few cases have been described to date. The onset of the symptoms in all pediatric patients appeared before the age of 8 and they developed end stage kidney disease (ESKD). They might manifest symptoms from the other systems.

类固醇抵抗是儿童肾病综合征的常见病。到目前为止,已经鉴定出50多个与激素抵抗性肾病综合征(SRNS)发病相关的基因,其中最常见的是NPHS1、NPHS2、CD2AP和PTPRO。SRNS的遗传模式为常染色体隐性遗传、常染色体显性遗传或线粒体遗传,这些患者的组织病理图像分析显示局灶节段性肾小球硬化(FSGS)征象。我们报告一例6岁女童因肾病范围蛋白尿及下肢水肿而入院儿科肾脏病科。我们开始使用强的松治疗,剂量为45mg (60mg /m2),依那普利作为肾保护,抗组胺药作为附加治疗。在住院治疗期间,我们检测到血压升高。尽管用最大剂量的类固醇治疗了6周,但由于持续的蛋白尿,我们证实了对类固醇的疾病抵抗。此外,肾活检样本也证实了FSGS征象。经SRNS基因筛查和罕见基因突变NUP93检测后,我们减少了强的松治疗,但仍维持肾保护治疗并给予环孢素a。女孩目前仍在肾科医生的护理下,动脉血压正常,随访检查微量蛋白尿,肾功能正常。NUP93突变极为罕见;因此,迄今为止很少有病例被描述。所有儿童患者的症状均出现在8岁之前,并发展为终末期肾病(ESKD)。他们可能会出现其他系统的症状。
{"title":"A rare cause of steroid-resistant nephrotic syndrome - a case report.","authors":"Paulina Kuran,&nbsp;Emilia Platos,&nbsp;Małgorzata Mizerska-Wasiak,&nbsp;Małgorzata Pańczyk-Tomaszewska","doi":"10.5114/ceji.2023.127534","DOIUrl":"https://doi.org/10.5114/ceji.2023.127534","url":null,"abstract":"<p><p>Steroid resistance is a common condition occurring in children with nephrotic syndrome. Until now, over 50 genes involved in steroid-resistant nephrotic syndrome (SRNS) pathogenesis have been identified, among which the most prevalent are NPHS1, NPHS2, CD2AP, and PTPRO. The patterns of inheritance of SRNS are autosomal recessive, autosomal dominant, or mitochondrial, and tissues of those patients show focal segmental glomerulosclerosis (FSGS) signs in histopathological image analysis. We present a case of a 6-year-old girl who was admitted to the pediatric nephrology department due to nephrotic range proteinuria and edema of the lower leg. We started therapy with prednisone at a dose of 45 mg (60 mg/m<sup>2</sup>), enalapril as a nephroprotection, and antihistamines as an additional treatment. During in-patient treatment, we detected increased blood pressure. Due to persistent proteinuria in spite of 6-week treatment with steroids at the maximal dose, we confirmed disease resistance to steroids. Additionally, FSGS signs were confirmed in kidney biopsy samples. After genetic screening for SRNS and detection of the rare gene mutation NUP93 we reduced prednisone but maintained nephroprotective treatment and administered cyclosporin A. The girl remains currently under the care of nephrologists with normal arterial blood pressure, trace proteinuria in follow-up examination, and normal kidney function. NUP93 mutation is extremely rare; therefore few cases have been described to date. The onset of the symptoms in all pediatric patients appeared before the age of 8 and they developed end stage kidney disease (ESKD). They might manifest symptoms from the other systems.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 2","pages":"158-162"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/a2/CEJI-48-50695.PMC10485693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effects of theophylline combined with inhaled corticosteroids on patients with moderate and severe asthma and changes of T lymphocyte subsets in peripheral blood. 茶碱联合吸入皮质类固醇对中重度哮喘患者外周血T淋巴细胞亚群的影响。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.127843
Xiaozhen Cai, Rong Rong, Yidan Huang, Xiaowen Pu, Nanhai Ge

Introduction: Asthma is a common respiratory disease. Theophylline combined with inhaled corticosteroids (ICS) is a promising therapy for asthma. This study explored the therapeutic effects of ICS combined with theophylline on moderate and severe asthma patients and T lymphocyte subsets (CD3+CD8+ T cells) in peripheral blood.

Material and methods: A total of 202 moderate and severe asthma patients were selected, with 101 treated with theophylline combined with ICS and 101 treated with ICS alone as controls. Lung function [forced expiratory volume within 1 second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF)] were tested using a spirometer. Asthma symptom control was evaluated by asthma control tests (ACT). The life quality was evaluated using the Asthma Quality of Life Questionnaire (AQLQ). The number and percentage of CD3+ T, CD3+CD4+ T and CD3+CD8+ T cells in peripheral blood mononuclear cells were assessed by flow cytometry. The correlation between CD3+CD8+ T cells and lung function and asthma control of patients after combination therapy was analyzed by Pearson correlation analysis.

Results: Compared with moderate and severe patients treated with ICS alone, theophylline improved the efficacy of ICS. Theophylline combined with ICS decreased IL-4 and IL-6 levels, and CD3+ T and CD3+CD8+ T cell number and percentage. After combined treatment, CD3+ CD8+ T cells in peripheral blood of patients were positively correlated with lung function and negatively correlated with asthma control.

Conclusions: The additional use of theophylline improved the efficacy of corticosteroids in asthma patient treatment and reduced inflammation level and CD3+ T and CD3+CD8+ T cell contents in peripheral blood.

哮喘是一种常见的呼吸系统疾病。茶碱联合吸入皮质类固醇(ICS)是一种很有前途的治疗哮喘的方法。本研究探讨ICS联合茶碱对中重度哮喘患者及外周血T淋巴细胞亚群(CD3+CD8+ T细胞)的治疗效果。材料与方法:选取202例中重度哮喘患者,其中茶碱联合ICS治疗101例,单独ICS治疗101例作为对照。使用肺活量计检测肺功能[1秒内用力呼气量(FEV1)、用力肺活量(FVC)和呼气峰值流量(PEF)]。通过哮喘控制试验(ACT)评估哮喘症状的控制情况。采用哮喘生活质量问卷(AQLQ)评价患者的生活质量。流式细胞术检测外周血单个核细胞中CD3+ T、CD3+CD4+ T和CD3+CD8+ T细胞的数量和百分比。采用Pearson相关分析CD3+CD8+ T细胞与联合治疗后患者肺功能及哮喘控制的相关性。结果:与单用ICS治疗的中重度患者相比,茶碱能提高ICS的疗效。茶碱联合ICS降低IL-4和IL-6水平,降低CD3+ T和CD3+CD8+ T细胞数量和百分比。综合治疗后,患者外周血CD3+ CD8+ T细胞与肺功能呈正相关,与哮喘控制呈负相关。结论:额外使用茶碱可提高皮质类固醇治疗哮喘患者的疗效,降低炎症水平和外周血CD3+ T和CD3+CD8+ T细胞含量。
{"title":"Effects of theophylline combined with inhaled corticosteroids on patients with moderate and severe asthma and changes of T lymphocyte subsets in peripheral blood.","authors":"Xiaozhen Cai,&nbsp;Rong Rong,&nbsp;Yidan Huang,&nbsp;Xiaowen Pu,&nbsp;Nanhai Ge","doi":"10.5114/ceji.2023.127843","DOIUrl":"https://doi.org/10.5114/ceji.2023.127843","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is a common respiratory disease. Theophylline combined with inhaled corticosteroids (ICS) is a promising therapy for asthma. This study explored the therapeutic effects of ICS combined with theophylline on moderate and severe asthma patients and T lymphocyte subsets (CD3<sup>+</sup>CD8<sup>+</sup> T cells) in peripheral blood.</p><p><strong>Material and methods: </strong>A total of 202 moderate and severe asthma patients were selected, with 101 treated with theophylline combined with ICS and 101 treated with ICS alone as controls. Lung function [forced expiratory volume within 1 second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF)] were tested using a spirometer. Asthma symptom control was evaluated by asthma control tests (ACT). The life quality was evaluated using the Asthma Quality of Life Questionnaire (AQLQ). The number and percentage of CD3<sup>+</sup> T, CD3<sup>+</sup>CD4<sup>+</sup> T and CD3<sup>+</sup>CD8<sup>+</sup> T cells in peripheral blood mononuclear cells were assessed by flow cytometry. The correlation between CD3<sup>+</sup>CD8<sup>+</sup> T cells and lung function and asthma control of patients after combination therapy was analyzed by Pearson correlation analysis.</p><p><strong>Results: </strong>Compared with moderate and severe patients treated with ICS alone, theophylline improved the efficacy of ICS. Theophylline combined with ICS decreased IL-4 and IL-6 levels, and CD3<sup>+</sup> T and CD3<sup>+</sup>CD8<sup>+</sup> T cell number and percentage. After combined treatment, CD3<sup>+</sup> CD8<sup>+</sup> T cells in peripheral blood of patients were positively correlated with lung function and negatively correlated with asthma control.</p><p><strong>Conclusions: </strong>The additional use of theophylline improved the efficacy of corticosteroids in asthma patient treatment and reduced inflammation level and CD3<sup>+</sup> T and CD3<sup>+</sup>CD8<sup>+</sup> T cell contents in peripheral blood.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 2","pages":"135-143"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/09/CEJI-48-50786.PMC10485692.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abnormal expression of CXCL13, MIF and IL-35 in patients with primary Sjögren's syndrome and its relationship with disease severity. 原发性Sjögren综合征患者CXCL13、MIF和IL-35的异常表达及其与病情严重程度的关系
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.127536
Ronghua Wang, Yushu Yang, Xuying Liu, Lingyan Lei, Xuan Qi

Introduction: The aim of the study was to detect the saliva chemokine (C-X-C motif) ligand 13 (CXCL13), macrophage migration inhibitory factor (MIF), and interleukin 35 (IL-35) levels in patients with primary Sjögren's syndrome (pSS) and pSS-associated interstitial lung disease (pSS-ILD), and to explore the relationship between CXCL13, MIF, IL-35 levels, and disease severity.

Material and methods: ESSDAI score was used to evaluate the disease activity of pSS patients, and the levels of CXCL13, MIF and IL-35 in saliva of subjects were detected and analyzed, and the relationship between CXCL13, MIF, IL-35 and the occurrence of pSS was evaluated. Pearson's correlation coefficient was used to analyze the correlation between CXCL13, MIF, IL-35 and ESSDAI score. ROC curve analysis was conducted to assess the diagnostic value of CXCL13, MIF, IL-35 and their combined application in pSS.

Results: The levels of CXCL13, MIF, and IL-35 in saliva were positively correlated with ESSDAI score. Saliva CXCL13 and IL-35 are risk factors for the development of pSS into pSS-ILD. The ROC curve shows that the combination of saliva CXCL13, MIF and IL-35 has the highest diagnostic efficiency for pSS-ILD.

Conclusions: CXCL13, MIF and IL-35 are related to the activity of pSS, and the combined diagnosis of these three indexes is expected to be an important method to predict the occurrence and development of pSS.

摘要:本研究旨在检测原发性Sjögren综合征(pSS)和pSS相关性间质性肺疾病(pSS- ild)患者唾液趋化因子(C-X-C motif)配体13 (CXCL13)、巨噬细胞迁移抑制因子(MIF)和白细胞介素35 (IL-35)水平,探讨CXCL13、MIF、IL-35水平与疾病严重程度的关系。材料与方法:采用ESSDAI评分法评价pSS患者的疾病活动性,检测分析受试者唾液中CXCL13、MIF、IL-35的水平,评价CXCL13、MIF、IL-35与pSS发生的关系。采用Pearson相关系数分析CXCL13、MIF、IL-35与ESSDAI评分的相关性。采用ROC曲线分析,评价CXCL13、MIF、IL-35及其联合应用对pSS的诊断价值。结果:唾液中CXCL13、MIF、IL-35水平与ESSDAI评分呈正相关。唾液CXCL13和IL-35是pSS发展为pSS- ild的危险因素。ROC曲线显示,唾液CXCL13、MIF和IL-35联合检测对pSS-ILD的诊断效率最高。结论:CXCL13、MIF、IL-35与pSS活性相关,三者联合诊断有望成为预测pSS发生发展的重要方法。
{"title":"Abnormal expression of CXCL13, MIF and IL-35 in patients with primary Sjögren's syndrome and its relationship with disease severity.","authors":"Ronghua Wang,&nbsp;Yushu Yang,&nbsp;Xuying Liu,&nbsp;Lingyan Lei,&nbsp;Xuan Qi","doi":"10.5114/ceji.2023.127536","DOIUrl":"https://doi.org/10.5114/ceji.2023.127536","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to detect the saliva chemokine (C-X-C motif) ligand 13 (CXCL13), macrophage migration inhibitory factor (MIF), and interleukin 35 (IL-35) levels in patients with primary Sjögren's syndrome (pSS) and pSS-associated interstitial lung disease (pSS-ILD), and to explore the relationship between CXCL13, MIF, IL-35 levels, and disease severity.</p><p><strong>Material and methods: </strong>ESSDAI score was used to evaluate the disease activity of pSS patients, and the levels of CXCL13, MIF and IL-35 in saliva of subjects were detected and analyzed, and the relationship between CXCL13, MIF, IL-35 and the occurrence of pSS was evaluated. Pearson's correlation coefficient was used to analyze the correlation between CXCL13, MIF, IL-35 and ESSDAI score. ROC curve analysis was conducted to assess the diagnostic value of CXCL13, MIF, IL-35 and their combined application in pSS.</p><p><strong>Results: </strong>The levels of CXCL13, MIF, and IL-35 in saliva were positively correlated with ESSDAI score. Saliva CXCL13 and IL-35 are risk factors for the development of pSS into pSS-ILD. The ROC curve shows that the combination of saliva CXCL13, MIF and IL-35 has the highest diagnostic efficiency for pSS-ILD.</p><p><strong>Conclusions: </strong>CXCL13, MIF and IL-35 are related to the activity of pSS, and the combined diagnosis of these three indexes is expected to be an important method to predict the occurrence and development of pSS.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 2","pages":"144-149"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/06/CEJI-48-50697.PMC10485687.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10587668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A biomarker and molecular mechanism investigation for thyroid cancer. 甲状腺癌症的生物标志物和分子机制研究。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 Epub Date: 2023-09-29 DOI: 10.5114/ceji.2023.132163
Keju Xie

Introduction: This study aimed to reveal the potential molecular mechanism associated with thyroid cancer (THCA) prognosis, and investigate promising biomarkers for THCA.

Material and methods: Differentially expressed genes (DEGs) were compared between THCA samples (THCA group) and normal samples (N group). Then, enrichment analysis and protein-protein interaction (PPI) network analysis were performed, followed by prognostic hub gene exploration from the PPI network. Furthermore, the prognostic and mutation analysis was performed on these hub genes. Finally, the associations of the hub gene with immune cells were investigated.

Results: A total of 802 DEGs were obtained between the THCA group and the N group. These DEGs were mainly enriched in pathways such as lysine degradation. From the PPI network, 20 hub genes, including CD44, CCND1, SNAI1, and KIT, were investigated. The survival analysis showed that the up-regulation of CD44 and down-regulation of SNAI1 contributed to the favorable and unfavorable outcomes of patients with THCA, respectively. Meanwhile, the diagnostic analysis showed that the AUC of KIT in THCA was larger than 0.9. Furthermore, the gene mutation analysis showed that the alternated CCND1 participated in the cell cycle pathway. Finally, the correlation analysis showed that prognostic genes such as CD44 were positively correlated with immune cells such as M1 macrophages.

Conclusions: A total of 20 hub genes including CCND1, CD44, SNAI1, and KIT were revealed as potential biomarkers for the differential diagnosis, prognosis, and development of drug targets of THCA. The lysine degradation pathway and cell cycle pathway might take part in the progression of THCA.

引言:本研究旨在揭示与甲状腺癌症(THCA)预后相关的潜在分子机制,并研究THCA有前景的生物标志物。材料和方法:比较THCA样品(THCA组)和正常样品(N组)的差异表达基因(DEGs)。然后,进行富集分析和蛋白质-蛋白质相互作用(PPI)网络分析,然后从PPI网络中进行预后中枢基因探索。此外,对这些中枢基因进行了预后和突变分析。最后,研究了hub基因与免疫细胞的关系。结果:THCA组和N组共获得802个DEG。这些DEG主要富集在赖氨酸降解等途径中。从PPI网络中,研究了20个枢纽基因,包括CD44、CCND1、SNAI1和KIT。生存分析显示,CD44的上调和SNAI1的下调分别有助于THCA患者的有利和不利结果。同时,诊断分析显示KIT在THCA中的AUC大于0.9。此外,基因突变分析表明,交替的CCND1参与了细胞周期途径。最后,相关性分析显示,CD44等预后基因与M1巨噬细胞等免疫细胞呈正相关。结论:共有20个枢纽基因,包括CCND1、CD44、SNAI1和KIT,被揭示为THCA鉴别诊断、预后和药物靶点开发的潜在生物标志物。赖氨酸降解途径和细胞周期途径可能参与THCA的进展。
{"title":"A biomarker and molecular mechanism investigation for thyroid cancer.","authors":"Keju Xie","doi":"10.5114/ceji.2023.132163","DOIUrl":"https://doi.org/10.5114/ceji.2023.132163","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to reveal the potential molecular mechanism associated with thyroid cancer (THCA) prognosis, and investigate promising biomarkers for THCA.</p><p><strong>Material and methods: </strong>Differentially expressed genes (DEGs) were compared between THCA samples (THCA group) and normal samples (N group). Then, enrichment analysis and protein-protein interaction (PPI) network analysis were performed, followed by prognostic hub gene exploration from the PPI network. Furthermore, the prognostic and mutation analysis was performed on these hub genes. Finally, the associations of the hub gene with immune cells were investigated.</p><p><strong>Results: </strong>A total of 802 DEGs were obtained between the THCA group and the N group. These DEGs were mainly enriched in pathways such as lysine degradation. From the PPI network, 20 hub genes, including CD44, CCND1, SNAI1, and KIT, were investigated. The survival analysis showed that the up-regulation of CD44 and down-regulation of SNAI1 contributed to the favorable and unfavorable outcomes of patients with THCA, respectively. Meanwhile, the diagnostic analysis showed that the AUC of KIT in THCA was larger than 0.9. Furthermore, the gene mutation analysis showed that the alternated CCND1 participated in the cell cycle pathway. Finally, the correlation analysis showed that prognostic genes such as CD44 were positively correlated with immune cells such as M1 macrophages.</p><p><strong>Conclusions: </strong>A total of 20 hub genes including CCND1, CD44, SNAI1, and KIT were revealed as potential biomarkers for the differential diagnosis, prognosis, and development of drug targets of THCA. The lysine degradation pathway and cell cycle pathway might take part in the progression of THCA.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 3","pages":"203-218"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticitrullinated antibodies recognize rheumatoid arthritis associated T-cell epitopes modified by bacterial L-asparaginase. 抗瓜氨酸抗体识别细菌L-天冬酰胺酶修饰的类风湿性关节炎相关T细胞表位。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 Epub Date: 2023-09-21 DOI: 10.5114/ceji.2023.131455
Tsvetelina Batsalova, Ivanka Teneva, Krum Bardarov, Dzhemal Moten, Balik Dzhambazov

Citrullinated proteins and anti-citrullinated protein antibodies (ACPAs) play an important role in the pathogenesis of rheumatoid arthritis (RA). It has been suggested that during inflammation or dysbiosis, bacteria could initiate production of ACPAs. Most patients with RA are seropositive for ACPAs, but these antibodies have overlapping reactivity to different posttranslational modifications (PTMs). For initiation and development of RA, T lymphocytes and T cell epitopes are still required. In this study, we evaluated the ability of bacterial L-asparaginase to modify RA-related T cell epitopes within type II collagen (CII259-273 and CII311-325), as well as whether these modified epitopes are recognized by ACPAs from RA patients. We included 12 patients with early RA and 11 healthy subjects selected according to predefined specific criteria. LC-MS/MS analyses revealed that the bacterial L-asparaginase can modify investigated T cell epitopes. ELISA tests showed cross-reactivity of ACPA positive sera from early RA patients towards the enzymatically modified immunodominant T cell epitopes within type II collagen (CII), but not to the modified irrelevant peptides. These data suggest that the cross-reactive ACPAs recognize the "carbonyl-Gly-Pro" motif in CII. Moreover, the T cell recognition of the modified major immunodominant T cell epitope Gal264-CII259-273 was not affected. This epitope was still able to activate autoreactive T cells from early RA patients. It is likely that such modifications are the missing link between the T cell priming and the development of anti-modified protein antibodies (AMPAs). Our results provide additional information on the etiology and pathogenesis of RA.

瓜氨酸蛋白和抗瓜氨酸蛋白抗体(ACPAs)在类风湿性关节炎(RA)的发病机制中起着重要作用。有人认为,在炎症或微生态失调期间,细菌可以启动ACPA的产生。大多数RA患者对ACPA呈血清阳性,但这些抗体对不同的翻译后修饰(PTM)具有重叠反应性。对于RA的起始和发展,仍然需要T淋巴细胞和T细胞表位。在本研究中,我们评估了细菌L-天冬酰胺酶修饰II型胶原内RA相关T细胞表位(CII259-273和CII311-325)的能力,以及这些修饰的表位是否被RA患者的ACPA识别。我们纳入了12名早期RA患者和11名根据预定义的特定标准选择的健康受试者。LC-MS/MS分析表明,细菌L-天冬酰胺酶可以修饰所研究的T细胞表位。ELISA测试显示,早期RA患者的ACPA阳性血清对II型胶原(CII)内酶修饰的免疫显性T细胞表位具有交叉反应性,但对修饰的无关肽没有交叉反应性。这些数据表明,交叉反应的ACPA识别CII中的“羰基Gly-Pro”基序。此外,T细胞对修饰的主要免疫显性T细胞表位Gal264-CII259-273的识别没有受到影响。该表位仍然能够激活早期RA患者的自身反应性T细胞。这种修饰很可能是T细胞启动和抗修饰蛋白抗体(AMPA)开发之间缺失的环节。我们的研究结果为RA的病因和发病机制提供了更多的信息。
{"title":"Anticitrullinated antibodies recognize rheumatoid arthritis associated T-cell epitopes modified by bacterial L-asparaginase.","authors":"Tsvetelina Batsalova,&nbsp;Ivanka Teneva,&nbsp;Krum Bardarov,&nbsp;Dzhemal Moten,&nbsp;Balik Dzhambazov","doi":"10.5114/ceji.2023.131455","DOIUrl":"https://doi.org/10.5114/ceji.2023.131455","url":null,"abstract":"<p><p>Citrullinated proteins and anti-citrullinated protein antibodies (ACPAs) play an important role in the pathogenesis of rheumatoid arthritis (RA). It has been suggested that during inflammation or dysbiosis, bacteria could initiate production of ACPAs. Most patients with RA are seropositive for ACPAs, but these antibodies have overlapping reactivity to different posttranslational modifications (PTMs). For initiation and development of RA, T lymphocytes and T cell epitopes are still required. In this study, we evaluated the ability of bacterial L-asparaginase to modify RA-related T cell epitopes within type II collagen (CII259-273 and CII311-325), as well as whether these modified epitopes are recognized by ACPAs from RA patients. We included 12 patients with early RA and 11 healthy subjects selected according to predefined specific criteria. LC-MS/MS analyses revealed that the bacterial L-asparaginase can modify investigated T cell epitopes. ELISA tests showed cross-reactivity of ACPA positive sera from early RA patients towards the enzymatically modified immunodominant T cell epitopes within type II collagen (CII), but not to the modified irrelevant peptides. These data suggest that the cross-reactive ACPAs recognize the \"carbonyl-Gly-Pro\" motif in CII. Moreover, the T cell recognition of the modified major immunodominant T cell epitope Gal264-CII259-273 was not affected. This epitope was still able to activate autoreactive T cells from early RA patients. It is likely that such modifications are the missing link between the T cell priming and the development of anti-modified protein antibodies (AMPAs). Our results provide additional information on the etiology and pathogenesis of RA.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 3","pages":"174-188"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel inflammatory markers in patients with severe COVID-19 and a pulmonary thrombotic event. 严重新冠肺炎和肺血栓事件患者的新炎症标志物。
IF 1.5 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 Epub Date: 2023-09-21 DOI: 10.5114/ceji.2023.131382
Jarosław Bakiera, Karolina Strzelec-Pawełczak, Katarzyna Czarnek, Ida Osuchowska-Grochowska, Jacek Bogucki, Agnieszka Markiewicz-Gospodarek, Aleksandra Górska, Zuzanna Chilimoniuk, Sebastian Radej, Mateusz Szymański, Piero Portincasa, Cezary Grochowski

Venous thromboembolism (VTE), clinically manifested as deep vein thrombosis (DVT) or acute pulmonary embolism (PE), is the third most common acute cardiovascular syndrome following myocardial infarction and stroke. The annual incidence of PE is between 39 and 115 per 100,000 inhabitants. The incidence of VTE is almost eight times higher in people aged 80 and older than in the fifth decade of life. We performed a retrospective study of 226 COVID-19 patients and selected group of patients who experienced a pulmonary thrombotic event. The incidence of PE in hospitalized COVID-19 patients was approximately 1.9-8.9%. The retrospective nature of the analyzed cohorts and relatively short observation periods could have led to underestimation of the actual incidence of PE. This study underlines the role of novel inflammatory biomarkers such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with a pulmonary thrombotic event in COVID-19. We suggest that these biomarkers may have high assessment value and complement routinely used biomarkers.

静脉血栓栓塞症(VTE),临床表现为深静脉血栓形成(DVT)或急性肺栓塞(PE),是继心肌梗死和中风之后第三常见的急性心血管综合征。PE的年发病率为每100000名居民39至115人。80岁及以上人群的VTE发病率几乎是生命第五个十年的八倍。我们对226名新冠肺炎患者和选择的一组经历过肺血栓事件的患者进行了回顾性研究。新冠肺炎住院患者的PE发病率约为1.9-8.9%。分析的队列的回顾性和相对较短的观察期可能导致低估PE的实际发病率。这项研究强调了新的炎症生物标志物,如中性粒细胞与淋巴细胞比率和血小板与淋巴细胞比率在新冠肺炎肺血栓事件患者中的作用。我们认为这些生物标志物可能具有较高的评估价值,并补充了常规使用的生物标志物。
{"title":"Novel inflammatory markers in patients with severe COVID-19 and a pulmonary thrombotic event.","authors":"Jarosław Bakiera, Karolina Strzelec-Pawełczak, Katarzyna Czarnek, Ida Osuchowska-Grochowska, Jacek Bogucki, Agnieszka Markiewicz-Gospodarek, Aleksandra Górska, Zuzanna Chilimoniuk, Sebastian Radej, Mateusz Szymański, Piero Portincasa, Cezary Grochowski","doi":"10.5114/ceji.2023.131382","DOIUrl":"10.5114/ceji.2023.131382","url":null,"abstract":"<p><p>Venous thromboembolism (VTE), clinically manifested as deep vein thrombosis (DVT) or acute pulmonary embolism (PE), is the third most common acute cardiovascular syndrome following myocardial infarction and stroke. The annual incidence of PE is between 39 and 115 per 100,000 inhabitants. The incidence of VTE is almost eight times higher in people aged 80 and older than in the fifth decade of life. We performed a retrospective study of 226 COVID-19 patients and selected group of patients who experienced a pulmonary thrombotic event. The incidence of PE in hospitalized COVID-19 patients was approximately 1.9-8.9%. The retrospective nature of the analyzed cohorts and relatively short observation periods could have led to underestimation of the actual incidence of PE. This study underlines the role of novel inflammatory biomarkers such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with a pulmonary thrombotic event in COVID-19. We suggest that these biomarkers may have high assessment value and complement routinely used biomarkers.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 3","pages":"167-173"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value and immunological role of PTPN21 in pan-cancer analysis. PTPN21在泛癌分析中的预后价值及免疫学作用。
IF 1.3 4区 医学 Q4 IMMUNOLOGY Pub Date : 2023-01-01 DOI: 10.5114/ceji.2023.129970
YanE Yang, WenChao Yang, Xingxing Su, CaiXia Cheng

Introduction: At present, cancer remains a persistent public health challenge facing the whole world. Studies have found that PTPN21 is associated with the development of cancer. However, the prognostic potential of PTPN21 in pan-cancer remains unclear. In this work, we aimed to analyze the expression and prognostic value of PTPN21 in pan-cancer and to further study the relationship between PTPN21 and immune infiltration.

Material and methods: TCGA and GEO data were used for expression and survival analysis. Genetic alterations in PTPN21 from TCGA cancer were studied in cBioPortal. TIMER2 was used to evaluate the correlation between PTPN21 expression and immune infiltration. The R packages "ggplot2" and "clusterProfiler" were used for GO and KEGG analysis.

Results: PTPN21 was found to be a valuable diagnostic biomarker in multiple cancers, including bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and lung squamous cell carcinoma (LUSC). In addition, we observed that PTPN21 expression was associated with a variety of tumor mutations. Our results indicated a correlation between PTPN21 expression and immune infiltration. Enrichment analysis showed that PTPN21 was mainly involved in the regulation of neuroactive ligand-receptor interaction.

Conclusions: Our study showed that PTPN21 expression is associated with clinical prognosis, mutation, and immune infiltration of tumors. PTPN21 may be a potential biomarker for many cancers, especially in KIRC.

目前,癌症仍然是全世界面临的一个持久的公共卫生挑战。研究发现,PTPN21与癌症的发展有关。然而,PTPN21在泛癌中的预后潜力尚不清楚。本研究旨在分析PTPN21在泛癌组织中的表达及预后价值,进一步研究PTPN21与免疫浸润的关系。材料和方法:采用TCGA和GEO数据进行表达和生存分析。研究了TCGA癌PTPN21基因的改变。采用TIMER2评价PTPN21表达与免疫浸润的相关性。使用R软件包“ggplot2”和“clusterProfiler”进行GO和KEGG分析。结果:PTPN21在膀胱尿路上皮癌(BLCA)、肾透明细胞癌(KIRC)、肾乳头状细胞癌(KIRP)和肺鳞状细胞癌(LUSC)等多种癌症中具有重要的诊断价值。此外,我们观察到PTPN21的表达与多种肿瘤突变有关。我们的结果表明PTPN21的表达与免疫浸润相关。富集分析表明,PTPN21主要参与神经活性配体-受体相互作用的调节。结论:我们的研究表明PTPN21的表达与临床预后、突变和肿瘤的免疫浸润有关。PTPN21可能是许多癌症的潜在生物标志物,尤其是KIRC。
{"title":"Prognostic value and immunological role of PTPN21 in pan-cancer analysis.","authors":"YanE Yang,&nbsp;WenChao Yang,&nbsp;Xingxing Su,&nbsp;CaiXia Cheng","doi":"10.5114/ceji.2023.129970","DOIUrl":"https://doi.org/10.5114/ceji.2023.129970","url":null,"abstract":"<p><strong>Introduction: </strong>At present, cancer remains a persistent public health challenge facing the whole world. Studies have found that PTPN21 is associated with the development of cancer. However, the prognostic potential of PTPN21 in pan-cancer remains unclear. In this work, we aimed to analyze the expression and prognostic value of PTPN21 in pan-cancer and to further study the relationship between PTPN21 and immune infiltration.</p><p><strong>Material and methods: </strong>TCGA and GEO data were used for expression and survival analysis. Genetic alterations in PTPN21 from TCGA cancer were studied in cBioPortal. TIMER2 was used to evaluate the correlation between PTPN21 expression and immune infiltration. The R packages \"ggplot2\" and \"clusterProfiler\" were used for GO and KEGG analysis.</p><p><strong>Results: </strong>PTPN21 was found to be a valuable diagnostic biomarker in multiple cancers, including bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and lung squamous cell carcinoma (LUSC). In addition, we observed that PTPN21 expression was associated with a variety of tumor mutations. Our results indicated a correlation between PTPN21 expression and immune infiltration. Enrichment analysis showed that PTPN21 was mainly involved in the regulation of neuroactive ligand-receptor interaction.</p><p><strong>Conclusions: </strong>Our study showed that PTPN21 expression is associated with clinical prognosis, mutation, and immune infiltration of tumors. PTPN21 may be a potential biomarker for many cancers, especially in KIRC.</p>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":"48 2","pages":"111-125"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/d0/CEJI-48-51128.PMC10485688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10569893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Central European Journal of Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1